Biocon receives FDA report, can start supplies to US from Vizag facility
With this approval, Biocon is authorised to begin commercial supplies from this greenfield active pharmaceutical ingredient (API) facility to the US market. Shares of Biocon Ltd ended at ₹359.30, up by ₹4.05, or 1.14%, on the BSE.